|Bid||13.90 x 1200|
|Ask||13.95 x 1300|
|Day's range||13.20 - 14.03|
|52-week range||1.92 - 19.36|
|Beta (5Y monthly)||1.34|
|PE ratio (TTM)||N/A|
|Earnings date||11 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||13.29|
Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) for breaches of fiduciary duties and violations of the Securities Exchange Act of 1934. Inovio is a late-stage biotechnology Company that focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines.
Novavax announced it would begin human trials for its coronavirus vaccine, while COVID-19 engulfs Brazil.
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy.
"We saw antibody responses that do many of the things we would want to see in an eventual vaccine," said Dr. David Weiner, director of the vaccine and immunotherapy center at the Wistar Institute, which has collaborated with Inovio. There are currently no approved treatments or vaccines for COVID-19, the disease caused by the new coronavirus, with governments, drugmakers and researchers working on around 100 vaccine programs. Many other drugmakers including Moderna Inc, Pfizer Inc, Johnson & Johnson, Sanofi and AstraZeneca Plc are also in various stages of vaccine development.
RBC Capital analyst Gregory Renza maintained a Hold rating on Inovio Pharmaceuticals (NASDAQ:INO) on Monday, setting a price target of $9, which is approximately 24.37% below the present share price of $11.9.
Barbuto & Johansson, P.A. (“BARJO”) reminds investors that today is the last day to contact the Firm to learn more about the class action filed against Inovio Pharmaceuticals, Inc. (INO), and appointment of lead plaintiff. The class action, McDermid v. Inovio Pharmaceuticals, Inc., et al., 2:20-cv-01402, was filed in the US District Court for the Eastern District of Pennsylvania on behalf of shareholders who purchased Inovio securities between February 14, 2020 and March 9, 2020, inclusive (the “Class Period”).
NEW YORK, May 11, 2020 -- In a release issued today by The Rosen Law Firm, P.A. under the headline "INO FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Reminds Inovio.
NEW YORK, May 11, 2020 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between February.
One welcome sign with the COVID-19 pandemic is how many companies, both large and small, have scrambled to develop diagnostic tests, antiviral treatments, and vaccines. Sure, these companies are in business to make money and have a profit motive behind their efforts. Inovio Pharmaceuticals (NASDAQ: INO) ranks as one of the leaders in the race to develop a COVID-19 vaccine.
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (INO) of the May 12, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Inovio stock or options between February 14, 2020 and March 9, 2020 and would like to discuss your legal rights, click here: http://www.faruqilaw.com/INO. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until May 12, 2020 to file lead plaintiff applications in a securities class action lawsuit against Inovio Pharmaceuticals (NasdaqGS: INO), if they purchased the Company’s shares between February 14, 2020 and March 9, 2020, both dates inclusive (the "Class Period"). This action is pending in the United States District Court for the Eastern District of Pennsylvania.
NEW ORLEANS, May 06, 2020 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending.
PHILADELPHIA, May 06, 2020 -- Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”).
CEDARHURST, N.Y., May 05, 2020 -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies..
NEW ORLEANS, May 04, 2020 -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:.
Inovio Pharmaceuticals (NASDAQ: INO) shares soared 61.7% in April, according to data provided by S&P Global Market Intelligence, as the company began human trials of its coronavirus vaccine. Inovio started a phase 1 trial of its DNA vaccine for COVID-19, the illness caused by the novel coronavirus, early in April and completed enrollment of 40 healthy adults later in the month. The clinical stage company also said it expanded its agreement with Richter-Helm BioLogics GmbH & Co. of Germany to cover large-scale manufacturing of the vaccine.
Robbins Geller Rudman & Dowd LLP announces that a securities class action lawsuit has been filed in the Eastern District of Pennsylvania on behalf of purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) common stock between February 14, 2020 and March 9, 2020 (the "Class Period"). The case is captioned McDermid v. Inovio Pharmaceuticals, Inc., No. 20-cv-01402, and is assigned to Judge Gerald J. Pappert. The Inovio Pharmaceuticals securities class action lawsuit charges Inovio Pharmaceuticals ("Inovio") and its current Chief Executive Officer J. Joseph Kim ("Kim") with violations of the Securities Exchange Act of 1934.